A Cure for HIV in the next decade?


Chris Armstrong
Raman Battish
John Billelo
Akeed Habeeb




The importance of a cure:



Figure of AIDS's attack on a cell


Reverse Transcriptase Inhibitors



It is at this point where special drugs, reverse transcriptase inhibitors, are used.
Two examples of these drugs are AZT and 3TC.

AZT = 3'-Azido-3'deoxythymidine
AZT is a prodrug which means that it is taken in its inactive form, then converted to its active form in the body through several metabolic steps. During this step, three phosphate groups are attached to the AZT molecule. This activated AZT molecule inserts itself into the growing DNA strand, preventing the completion of the HIV's replication.

A drawback of AZT is that the second phosphate group is added very slowly which leads to the accumulation of the monophosphate AZT molecule, which leads to the harmful side-effects associated with AZT.
Also, with therapy of only AZT alone, the virus becomes resistant to the drug.

This calls for a need to combine AZT with other drugs.
However, for many on combination-antiretroviral therapy the demands of the treatments are hard to comply with consistently. This is because many pills need to be taken each day, some pills have to be taken with food, some without food, etc.

A new drug has just been approved (September 29, 1997), Combivir, which combines AZT and 3TC in one pill that only needs to be taken twice a day




Integrase Inhibitors

Integrase = the protein that incorporates the virus's DNA into the host cell's genome.
Crtitical Step : genetically altered HIV lacking the integrase gene cannot infect cells.

    ADVANTAGES:
  • No interase activity in normal cells
  • Attacks virus at a different point in its life cycle

    DISADVANTAGES:
  • Acts only for a single brief step in life cycle
  • "Escape Mutants"

    ZINTEVIR:
  • Aronex pharmaceuticals
  • Stable oligonucleotide administered via IV-infusion
    • Side effects:
    • heartburn
    • headache
    • dizziness
    • slowed heart rate
    • bleeding gums
    • Clinical trials are succesful




    Protease Inhibitors


    Figure of the HIV genome

    • Thus, if we can inhibit these proteases from cutting the gag-pol-env complex, viral incorporation will not occur.
    • Stop HIV's progression in a host/patient.


    Some experimental protease inhibitors:

      • Indinvir
      • Nelfinavir
      • Ritonavir
      • Saquinavir

    • Recommended for use with RT and integrase inhibitors



    Commercially available protease inhibitor

    • Viracept
    Present day protease inhibitors are not a cure, but a treatment.



    HIV Vaccines


      ADVANTAGES:
    • Experts agree a vaccine is the best solution
      • Global effects:
      • affordable
      • readily available
    • Eradication (example: smallpox)

      DISADVANTAGES:
    • Large variability of the HIV.
    • Mutates repidly as infection spreads.
    • Unknown infectivity process.
    • Immune response may be not afford immunity.

      CURRENT VACCINES:
        SIV Vaccine:
      • Dr. Ronald Desrosiers
      • Simian immunodeficiency virus (HIV for monkeys)
      • Classic approach - attenuated form of virus (nef gene removed)
      • Succesful trials in monkeys
      • Application in humans?
        Remune:
      • Jonas Salk
      • Inactivated HIV-1 virus with part of viral envelope (gp-120) removed
      • Clinical trials have found it to be effective




    Conclusions

      TREATMENT:
    • Combination therapy, using all three strategies (Reverse Transcriptase Inhibitors, Integrase Inhibitors, and Protease Inhibitors), will reduce replication rate of HIV and thus lower the number of mutant strains
    • However, these are treatments, NOT cures. These may extend patient lives, but will not eradicate HIV.
      CURE:
    • The only way to cure HIV (other than safer sexual and hypodermic needle practices), is to find a vaccine.
    • However, our investgations found no evidence pointing towards the acquisition of a working HIV vaccine within the near future.




    Click here to return to the Introduction Page